

**bs-5068R****[ Primary Antibody ]****BioSS**  
ANTIBODIES

www.bioss.com.cn


sales@bioss.com.cn

techsupport@bioss.com.cn

400-901-9800

**HMGCR Rabbit pAb****DATASHEET**

<b>Host:</b> Rabbit	<b>Isotype:</b> IgG	<b>Applications:</b> WB (1:500-2000)
<b>Clonality:</b> Polyclonal		<b>Reactivity:</b> Human
<b>GeneID:</b> 3156	<b>SWISS:</b> P04035	
<b>Target:</b> HMGCR		
<b>Immunogen:</b> KLH conjugated synthetic peptide derived from human HMGCR: 251-350/888.		<b>Predicted MW.:</b> 97 kDa
<b>Purification:</b> affinity purified by Protein A		<b>Subcellular Location:</b> Cell membrane ,Cytoplasm
<b>Concentration:</b> 1mg/ml		
<b>Storage:</b> 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.		
<b>Background:</b> HMG-CoA reductase is the rate-limiting enzyme for cholesterol synthesis and is regulated via a negative feedback mechanism mediated by sterols and non-sterol metabolites derived from mevalonate, the product of the reaction catalyzed by reductase. Normally in mammalian cells this enzyme is suppressed by cholesterol derived from the internalization and degradation of low density lipoprotein (LDL) via the LDL receptor. Competitive inhibitors of the reductase induce the expression of LDL receptors in the liver, which in turn increases the catabolism of plasma LDL and lowers the plasma concentration of cholesterol, an important determinant of atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq].		

**VALIDATION IMAGES**

25 ug total protein per lane of various lysates (see on figure) probed with HMGCR polyclonal antibody, unconjugated (bs-5068R) at 1:2000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.

**SELECTED CITATIONS**

- **[IF=10.5]** Hongxin Tan. et al. Endoplasmic reticulum-targeted biomimetic nanoparticles induce apoptosis and ferroptosis by regulating endoplasmic reticulum function in colon cancer. J CONTROL RELEASE. 2024 Nov;375:422 IF ;Mouse. 39278355
- **[IF=9.423]** Wen-Long Sun. et al. Myricetin supplementation decreases hepatic lipid synthesis and inflammation by modulating gut microbiota. Cell Rep. 2021 Aug;36:109641 WB ;Rat. 34469716
- **[IF=8.063]** Hu ZB et al. Dysbiosis of intestinal microbiota mediates tubulointerstitial injury in diabetic nephropathy via the disruption of cholesterol homeostasis. Theranostics. 2020 Feb 3;10(6):2803-2816. IHC,IF ;rat. 32194836

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

- **[IF=6.78]** Shuzhou Wang. et al. Effects of NAC assisted insulin on cholesterol metabolism disorders in canine type 1 diabetes mellitus. LIFE SCI. 2022 Dec;;121193 WB ;Dog. 36463942
- **[IF=5.5]** Fu et al. Lack of CLC-2 Alleviates High Fat Diet-Induced Insulin Resistance and Non-Alcoholic Fatty Liver Disease. (2018) Cell.Physiol.Biochem. 45:2187-2200 WB ;Mouse. 29550812